Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 01, 2018 09:05 ET | Source: Cantabio Pharmaceuticals Inc.

Cantabio Pharmaceuticals to Present Latest Positive In Vivo Results From its DJ-1 Targeting Small Molecule Drug Development Program for Parkinson’s Disease at the Milner Therapeutics Symposium at the University of Cambridge, UK

SAN FRANCISCO, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Cantabio Pharmaceuticals Inc. (OTCQB: CTBO), a biopharmaceutical company developing novel disease modifying therapies for Alzheimer's (AD),...
July 31, 2018 07:20 ET | Source: Cantabio Pharmaceuticals Inc.

Cantabio Pharmaceuticals to Present Positive in vivo Efficacy Results in a Mice Model of Parkinson’s disease of One of Its Orally Administered Novel DJ-1 Protein Targeting Therapeutic Candidates at the XXV International Symposium on Medicinal Chemistry in Ljubljana, Slovenia

SAN FRANCISCO, July 31, 2018 (GLOBE NEWSWIRE) -- Cantabio Pharmaceuticals Inc. (OTCQB:CTBO), a biopharmaceutical company developing novel disease modifying therapies for Alzheimer's (AD),...
June 28, 2018 09:02 ET | Source: Cantabio Pharmaceuticals Inc.

Cantabio Announces Publication of Study on Druggability of the Tau protein in ACS Chemical Neuroscience

Structural biology based evidence shows that native monomeric Tau can be a viable target for drug-like small molecules, despite its heterogeneous structure SUNNYVALE, Calif., June 28, 2018 (GLOBE...
May 09, 2018 08:18 ET | Source: Cantabio Pharmaceuticals Inc.

Cantabio Pharmaceuticals to Present Positive in vivo Efficacy Data in a Mice Model of Parkinson’s disease from Its DJ-1 Protein Targeting Therapeutic Program at the Neuro4D Conference in Mainz, Germany

SAN FRANCISCO, May 09, 2018 (GLOBE NEWSWIRE) -- Cantabio Pharmaceuticals Inc. (OTCQB:CTBO), a biopharmaceutical company developing novel disease modifying therapies for Alzheimer's (AD), Parkinson's...
September 19, 2016 09:00 ET | Source: Cantabio Pharmaceuticals Inc.

Cantabio Pharmaceuticals to Present at 2016 Silicon Valley Bank Healthcare Capital and Connections Summit in Shanghai

SAN FRANCISCO, Sept. 19, 2016 (GLOBE NEWSWIRE) -- Cantabio Pharmaceuticals, Inc. (OTCQB:CTBO), a biopharmaceutical company developing novel disease modifying therapies for Alzheimer’s, Parkinson’s...
September 07, 2016 10:18 ET | Source: Cantabio Pharmaceuticals Inc.

Cantabio Pharmaceuticals licenses Tau protein targeting therapeutic program from University of Cambridge for the potential treatment of Alzheimer’s Disease and related Dementias

SAN FRANCISCO and CAMBRIDGE, United Kingdom, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Cantabio Pharmaceuticals, Inc. (OTCQB:CTBO) today announced the completion of a licensing agreement with Cambridge...
August 18, 2016 08:50 ET | Source: Cantabio Pharmaceuticals Inc.

Cantabio Pharmaceuticals to Present Results from its DJ-1 Protein Targeting Therapeutic Programs at the 4th World Parkinson’s Congress and 3rd International Parkinson’s Disease Symposium

SAN FRANCISCO, Calif., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Cantabio Pharmaceuticals, Inc. (OTCQB:CTBO), a biopharmaceutical company developing novel disease modifying therapies for Alzheimer’s,...
July 11, 2016 12:36 ET | Source: Cantabio Pharmaceuticals Inc.

Cantabio Pharmaceuticals and Purdue Research Foundation Sign Cooperation Agreement to Investigate the Targeting of DJ-1 Protein for Treating Parkinson’s Disease and Other Neurodegenerative Diseases

SAN FRANCISCO and WEST LAFAYETTE, Ind., July 11, 2016 (GLOBE NEWSWIRE) -- Cantabio Pharmaceuticals, Inc. (OTCQB:CTBO) today announced the signing of an agreement with Purdue Research Foundation...
June 16, 2016 09:46 ET | Source: Cantabio Pharmaceuticals Inc.

UPDATE -- Cantabio Pharmaceuticals and University of Antioquia Collaborate to Research Company’s Therapeutic Candidates Targeting DJ-1 Protein to Treat Parkinson’s Disease

SAN FRANCISCO, June 16, 2016 (GLOBE NEWSWIRE) -- Cantabio Pharmaceuticals, Inc. (OTCQB:CTBO) today announced its collaboration with the Neuroscience Research Group at the University of Antioquia in...
June 16, 2016 08:00 ET | Source: Cantabio Pharmaceuticals Inc.

Cantabio Pharmaceuticals and University of Antioquia Collaborate to Research Company’s Therapeutic Candidates Targeting DJ-1 Protein to Treat Parkinson’s Disease

SAN FRANCISCO, June 16, 2016 (GLOBE NEWSWIRE) -- Cantabio Pharmaceuticals, Inc. (OTCQB:CTBO) today announced its collaboration with the Neuroscience Research Group at the University of Antioquia...